Search - tctmd.com

Displaying 221 - 240 of 59296

Sort: Relevancy | Date

Presentation THT 2026

Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

Presenter: Hanna Gaggin

March 03, 2026

Presentation THT 2026

Bioelectric Regulation of Cardiac Remodeling in Heart Failure: Microcurrent Therapy

Presenter: Stefan Anker

March 03, 2026

Presentation THT 2026

The Special Cases of In- and Out-of Hospital Cardiac Arrest

Presenter: Maya Guglin

March 03, 2026

Presentation THT 2026

Identifying and Preventing Toxicity

Presenter: Eric D. Adler

March 03, 2026

Presentation THT 2026

Enhancing Risk Prediction With Novel Approaches To Define Cardiogenic Shock Phenotypes

Presenter: Jonas Sundermeyer

March 03, 2026

Presentation THT 2026

Wearable Cardiac Defibrillator for Newly Diagnosed HFrEF: Real World Evidence

Presenter: Marat Fudim

March 03, 2026

Presentation THT 2026

Real-World Outcomes of Eplerenone in Non-Obstructive Hypertrophic Cardiomyopathy

Presenter: Thitiphan Srikulmontri

March 03, 2026

Presentation THT 2026

SCAI Stages of Cardiogenic Shock: Past, Present and Future

Presenter: David A. Baran

March 03, 2026

Presentation THT 2026

Impact of Baseline Tricuspid Regurgitation on Outcomes in Heart Failure Patients Undergoing Mitral TEER

Presenter: Thitiphan Srikulmontri

March 03, 2026

Presentation THT 2026

Cardiac Contractility Modulation: Combining CCM and ICD Therapy

Presenter: Nir Uriel

March 03, 2026

Presentation THT 2026

Designing Studies for Gene Therapy for Rare Diseases

Presenter: Barry Greenberg

March 03, 2026

Presentation THT 2026

Keeping Patients out of DanGer

Presenter: Jacob Eifer Moeller

March 03, 2026

Presentation THT 2026

Central Venous Congestion in Transcatheter Tricuspid Repair: Lessons from the TRI.Fr Trial

Presenter: Karl-Philipp Rommel

March 03, 2026

Presentation THT 2026

Barostimulation Therapy for HFrEF

Presenter: Philip Adamson, MD

March 03, 2026

Presentation THT 2026

Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial

Presenter: Sanjiv J. Shah

March 03, 2026

Presentation THT 2026

Defining the Targets for Gene Therapy and Optimizing Vectors for Delivery

Presenter: Roger J. Hajjar

March 03, 2026

Presentation THT 2026

Medication Regimen Changes and Clinical Outcomes in the Cardiac Microcurrent (C-MIC) II Randomized Trial

Presenter: Marat Fudim

March 03, 2026

Presentation THT 2026

The Lymphatic System as a Target for ADHF

Presenter: Jan Biegus

March 03, 2026

Presentation THT 2026

Artificial Intelligence Meets Real-World Heart Failure: Early Results from the HF-TRACK Trial

Presenter: Shamus Husheer

March 03, 2026

Presentation THT 2026

Reducing Renal Venous Pressure to Improve Urine Output: Overview of Devices, Current Status, and Future Directions

Presenter: Arvind Bhimaraj

March 03, 2026

Advertisement

Characteristics associated with disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis

Bioelectric Regulation of Cardiac Remodeling in Heart Failure: Microcurrent Therapy

The Special Cases of In- and Out-of Hospital Cardiac Arrest

Identifying and Preventing Toxicity

Enhancing Risk Prediction With Novel Approaches To Define Cardiogenic Shock Phenotypes

Wearable Cardiac Defibrillator for Newly Diagnosed HFrEF: Real World Evidence

Real-World Outcomes of Eplerenone in Non-Obstructive Hypertrophic Cardiomyopathy

SCAI Stages of Cardiogenic Shock: Past, Present and Future

Impact of Baseline Tricuspid Regurgitation on Outcomes in Heart Failure Patients Undergoing Mitral TEER

Cardiac Contractility Modulation: Combining CCM and ICD Therapy

Designing Studies for Gene Therapy for Rare Diseases

Keeping Patients out of DanGer

Central Venous Congestion in Transcatheter Tricuspid Repair: Lessons from the TRI.Fr Trial

Barostimulation Therapy for HFrEF

Atrial Shunt for Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes from the REDUCE LAP-HF II Trial

Defining the Targets for Gene Therapy and Optimizing Vectors for Delivery

Medication Regimen Changes and Clinical Outcomes in the Cardiac Microcurrent (C-MIC) II Randomized Trial

The Lymphatic System as a Target for ADHF

Artificial Intelligence Meets Real-World Heart Failure: Early Results from the HF-TRACK Trial

Reducing Renal Venous Pressure to Improve Urine Output: Overview of Devices, Current Status, and Future Directions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content